Showing 2651-2660 of 4067 results for "".
- Global Study Highlights Emotional and Practical Drivers of Breast Augmentationhttps://reachmd.com/news/global-study-highlights-emotional-and-practical-drivers-of-breast-augmentation/2484851/Despite high satisfaction rates reported among breast augmentation recipients, uptake of the procedure remains relatively low worldwide. A new multinational study published in Aesthetic Surgery Journal Open Forum identifies key emotional motivators and per
- Engineering Advances in Drug Delivery: Polysorbate 80 and Blood-Brain Barrier Permeationhttps://reachmd.com/news/engineering-advances-in-drug-delivery-polysorbate-80-and-blood-brain-barrier-permeation/2484782/Polysorbate 80 minor components can selectively increase blood–brain barrier (BBB) permeation, providing a tunable formulation strategy to enhance CNS exposure for compatible drugs.
- Renerva's Pioneering Step in Neuroma Pain Management: IDE Approval for First-in-Human Study of PNM-CAP Devicehttps://reachmd.com/news/renervas-pioneering-step-in-neuroma-pain-management-ide-approval-for-first-in-human-study-of-pnm-cap-device/2484758/Renerva receives FDA IDE approval to open a first-in-human study of its PNM-CAP device aimed at preventing neuroma formation in amputees and reducing opioid reliance. Renerva has received
- Anesthesia Practice Transformation: Navigating 2026 Challenges and Opportunitieshttps://reachmd.com/news/anesthesia-practice-transformation-navigating-2026-challenges-and-opportunities/2484703/Workforce attrition and rapid ambulatory migration are reshaping anesthesia service models—forcing urgent adjustments to rostering and preoperative throughput to protect safety and capacity. Nearly 30% of practicing anesthesiologists are projected to leave clinical p
- Innovative Nanoformulations: Overcoming Chemotherapy Resistancehttps://reachmd.com/news/nanoformulations-chemotherapy-resistance/2484667/Paclitaxel–pterostilbene nanoparticles markedly increase paclitaxel solubility and antitumor activity, offering a direct translational route to overcome taxane resistance by enabling higher intratumoral delivery with less reliance on solvent excipients. Current paclitaxel formulation
- Enhancing Topical Antifungal Delivery: The Role of Nanoparticle Carriershttps://reachmd.com/news/enhancing-topical-antifungal-delivery-the-role-of-nanoparticle-carriers/2484654/Isoconazole nitrate nanoparticles (ISN‑NP) formulated into a Carbopol nanogel markedly increase skin uptake and antifungal potency, addressing the persistent problem of
- Exploring GB-5001 Long-acting Injectable Donepezil: A New Frontier in Dementia Treatmenthttps://reachmd.com/news/exploring-gb-5001-long-acting-injectable-donepezil-a-new-frontier-in-dementia-treatment/2484621/GB-5001, a long‑acting injectable formulation of donepezil, produces extended systemic exposure and—if confirmed in patient trials—could materially improve adherence in dementia care. A Phase 1, open‑label, active‑controlled dose‑escalation study enrolled 50 healthy
- Exploring the Shift to Oral GLP-1 Pills: Implications for Primary Carehttps://reachmd.com/news/exploring-the-shift-to-oral-glp-1-pills-implications-for-primary-care/2484634/Semaglutide's move into oral formulations from the makers of Wegovy could be a turning point for obesity management in primary care. The emergence of
- Trial for First Oral Minoxidil for Female Hair Loss Initiates Phase 3https://reachmd.com/news/trial-for-first-oral-minoxidil-for-female-hair-loss-launches-phase-3/2484534/Veradermics, Inc. announced the initiation of patient enrollment in a phase 2/3 registration-directed clinical trial of VDPHL01, a novel extended-release oral minoxidil formulation, according to a press release. If approved, V
- Unmasking the Hidden Survivors in Triple-Negative Breast Cancer: New Insights into Drug-Tolerant Persister Cellshttps://reachmd.com/news/unmasking-the-hidden-survivors-in-triple-negative-breast-cancer-new-insights-into-drug-tolerant-persister-cells/2484352/In the relentless fight against triple-negative breast cancer (TNBC), resistance to therapy remains one of the most formidable barriers to long-term remission.